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Background 
In September 2012, the Universite Cheikh Anta Diop, in collaboration with the London School of 
Hygiene & Tropical Medicine and the West African Roll Back Malaria Regional Network (WARN), 
convened a meeting in Praia, Cape Verde, to discuss implementation of Seasonal Malaria 
Chemoprevention (SMC). Participants included programme managers and staff of national malaria 
control programmes of WARN member countries, scientists involved in malaria control from 
research institutions in these countries, and representatives of UNICEF, MSF, Roll Back Malaria, and 
WHO. The purpose of the meeting was to discuss where, when and how SMC can be implemented in 
WARN countries, and to share experiences with implementation of SMC in large scale pilot projects. 
In Dakar in December WHO/BM convened a meeting of malaria control programme managers from 
the same countries to launch the SMC implementation guide, at which there was further discussion 
of the same issues. This report is a summary of the discussions and conclusions of these meetings.  
Recent progress in malaria control is threatened by emerging resistance of malaria parasites to 
artemisinins and of mosquitoes to commonly used insecticides. Nevertheless, malaria remains an 
important public health problem in many parts of Africa and there is unlikely to be a highly effective 
malaria vaccine for many years. New tools are urgently needed, and there is increasing recognition 
that effective control will require different strategies tailored to specific areas and populations. SMC 
is an example of this approach, suited to areas where malaria is highly seasonal and the burden of 
disease is primarily in young children. In March 2012, WHO recommended that children 3-59 months 
of age living in areas with highly seasonal malaria should receive a course of treatment with 
sulfadoxine-pyrimethamine plus amodiaquine each month, for up to four months, during the high 
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transmission period. Each month, one dose of SP and the first dose of AQ are given on the first day 
of treatment, and the second and third doses of AQ are given on the next two days. SMC with SP+AQ 
provides a very high degree of personal protection, with about 90% efficacy for up to 4 weeks after 
treatment. However, protection decreases rapidly thereafter it is therefore important that children 
receive treatments at intervals of one month to maximize protection and also to prevent parasite 
exposure to sub-therapeutic concentrations of drugs. This strict timing requires delivery through 
community health worker schemes, community case management schemes or mass campaigns 
which can reach all eligible children over a 2-5 day period each month. The regions most suited to 
SMC are those where malaria transmission is highly seasonal, and incidence is high. In such areas, 
the main burden of malaria is in young children and monthly chemoprevention provided to children 
for about 4 months of the year can prevent a large part of the total malaria burden.  
 
Policy process 
By December the process of incorporating SMC into malaria control policy had been initiated in 
Burkina Faso, Chad, The Gambia, Ghana, Guinea, Guinea Bissau, Mali, Niger, Nigeria and Senegal and 
most of these countries are expected to adopt the policy in 2012 or 2013. In Senegal, for example, 
workshops had been held to agree on the areas and age groups to be targeted for SMC, the National 
Malaria Control Programme has prepared a policy document covering SMC and two other new 
policies (rectal artesunate and ACT in pregnancy), a national consensus workshop had been held, 
and formal adoption of the policies by the Ministry of Health is expected early in 2013.  
 
Where and when to implement 
Identification of suitable areas for SMC should, ideally, be based on recent data on the incidence of 
parasitologically confirmed malaria, but this information is not available in most countries; an 
exception is Senegal, where nationally representative data on the incidence of malaria confirmed by 
RDT is available for 2008 and 2009 (Fig 1). Most countries have relied on MARA maps and some 
research data for stratification of the country. Using data on seasonality of clinically diagnosed 
malaria without parasitological confirmation will give an incorrect impression that malaria incidence 
is less strongly seasonal than it is. Collation of all available data on seasonality of confirmed malaria 
and more detailed mapping of areas suitable for SMC would be very useful. The regions currently 
targetted for SMC in each country are shown in Fig 2. It is not clear if large urban areas within these 
regions should be included.  
All countries have planned for delivery over 4 months of the year, but the timing differs, and varies  
between countries depending upon local epidemiology; from June to September (Guinea), July to 
October (Guinea Bissau, Chad, parts of Senegal and Mali), and August to November (Gambia, 
Burkina Faso, Niger, Burkina Faso, parts of Senegal and Mali). The estimated size of the targeted 
population in the  areas where SMC is planned, and the policy process has started, is 10.9million. In 
Nigeria and Ghana, the population of children in areas where SMC would be appropriate is 
11.2million in Nigeria and 0.5million in Ghana.  
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Togo, Benin, Central African Republic, Cameroon, South Sudan and Sudan were not represented at 
the meetings but include regions where SMC may be useful.  
SMC for children is intended as a tool to reduce the malaria burden in areas of high transmission; it 
is not a suitable tool for elimination. In areas where transmission has fallen the age distribution is 
more uniform across all ages and in these areas other malaria control strategies may be required.  
 
Age groups for SMC 
The WHO recommends SMC for children aged 3-59 months, although it also considered the 
possibility that in some areas older children might also benefit from SMC.  Raising the upper age 
limit to include older children was considered by some countries. The age distribution of 
parasitologically proven malaria cases admitted to hospital will provide useful information on which 
to base the age range appropriate for SMC. It is important that these data come from hospitals and 
health centres whose catchment population is in the area targeted for SMC. It may be misleading to 
use aggregated national data, or data from referral hospitals whose catchment includes urban areas 
and areas outside the zone targeted for SMC, if these areas have a lower transmission intensity the 
age distribution may not reflect the situation in the SMC areas. National reporting forms give 
aggregated figures only for under 5’s and persons 5 and above, and pregnant women (it would be 
helpful if standard reporting forms could be modified to give a finer breakdown by age). However 
data on ages of inpatient malaria cases from SMC areas could easily be collected from admissions 
books for health facilities serving the area targeted for SMC.  
The large-scale pilot schemes in Senegal included children up to 9 years of age, SMC with SP+AQ was 
safe and well tolerated in this age group. Raising the upper age limit from 4 to 9 years approximately 
doubled the number of children to be treated but there were economies of scale in terms of delivery 
as health workers could easily include older children during their household visits. For monthly 
rounds which occurred during term time, visits were planned after school hours and at weekends. 
The drug dosage for older children was 1 tablet of SP and 1 tablet per day of AQ, for children 5 years 
of age, and 1.5 tablets of SP and 1.5 tablets per day of AQ, for children 6-9 yrs of age. Increasing the 
age limit from 4 to 9 years increased the total cost of drugs by approximately 2.5 times when loose 
tablets were used. The overall cost of delivery was estimated to be $0.50 per child per month. Data 
from the SMC effectiveness study in Saraya indicates a substantial benefit of SMC in older children.  
 
Pilot schemes 
Three countries have implemented SMC in large-scale pilot schemes and benefited from this 
experience in planning scaling-up of SMC. Senegal has piloted SMC in five districts (Tivaouane from 
2007-2010, Mbour, Fatick and Bambey districts from 2008-2010, in central Senegal, and Saraya 
district in southern Senegal, 2011).  MSF conducted pilot schemes in Koutiala district, in southern 
Mali and in two areas of Moïssala district, in Chad, in 2011. In Senegal, SMC was implemented using 
two strategies - in central Senegal, through mass campaigns coordinated by the district health team 
using community health workers paid a daily rate who were managed locally by health posts, and in 
southern Senegal, through community case management using malaria volunteers and community 
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health workers resident in the village. In Mali and Chad, mass campaigns were organised each 
month using community health workers who delivered SMC at fixed points and door to door. In 
central Senegal, SMC was delivered over three months (September-November), in Southern Senegal 
over 5 months July-November (analysis showed that 4 months July to October would have been 
sufficient), and in Mali and Chad over 4 months (July to October).  
 
Management of breakthrough cases 
It is preferable that children who have received SMC with SP+AQ who experience a clinical episode 
of malaria should be treated, with a drug regimen that does not contain AQ or SP, although the 
WHO policy recommendation does not preclude use of ASAQ for children who have received SMC. 
Only two countries (Niger and Guinea) currently rely primarily on ASAQ for first line treatment; in 
Senegal, Gambia, Mali, and Guinea Bissau, AL is the first line, in Chad, Ghana, Nigeria, and Burkina 
Faso, AL and ASAQ are used. In addition DHA-PQ is used in Ghana and in Chad. Ideally in SMC areas, 
AL or DHA-PQ should be used for treatment of clinical malaria in children in areas where SMC is 
introduced.  
A child with a febrile illness who has received SMC in the last month is much less likely to have 
malaria than a child who has not had SMC. If SMC is introduced in areas where use of RDTs for 
malaria diagnosis is not routine, it would be highly desirable to introduce  RDTs  at the same time. If 
antimalarial treatment is given presumptively without requiring parasitological confirmation, 
children receiving SMC will receive many unnecessary treatments, and confidence in SMC may be 
undermined.  
WHO recommends that treatment for clinical malaria should be given wherever possible only after a 
positive parasitological diagnosis has been made,  most countries have adopted this policy but the 
extent to which this has been implemented on a national scale is variable. Most countries have 
planned SMC implementation in a phased manner, initially in small areas as a pilot, rapidly 
expanding to all the areas where SMC is appropriate. It would be highly desirable to introduce use of 
RDTs for parasitological diagnosis for malaria in all the areas where SMC will ultimately be delivered, 
at the start of the SMC pilot implementation. This will provide pre-implementation surveillance data 
which can serve as a baseline for measuring the impact of SMC.  
 
Supply chain 
Existing channels for supplying drugs to districts may be adequate, but careful planning will be 
needed to ensure timely supply of SMC drugs to districts at the start of each transmission season. To 
ensure adequate stocks are available at regional level, the number of SP and AQ tablets or treatment 
packs for infants and older children should be forecast from the estimated number of children under 
5 years of age in the target areas. Blister packs of SP and AQ for SMC are being reviewed by WHO for 
pre-qualification. Distribution from the district health centre to peripheral health facilities and to 
villages may be done monthly, for areas that become inaccessible during the rainy season adequate 
supplies for the season can be delivered at the start of the season.  
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Monitoring and Evaluation 
Monitoring and Evaluation (M&E). Plans for M&E are not yet well developed. SMC can be 
incorporated into existing Health Management Information Systems to monitor process inputs and 
outcomes and impact indicators. This will need to be supplemented by incorporating coverage of 
SMC in MIS and DHS surveys. Accurate, complete and durable documentation of dates of doses is 
essential to permit assessment of coverage, measurement of efficacy using case control studies, and 
for pharmacovigilance. Partnership with researchers will be necessary to conduct monitoring of SMC 
efficacy and parasitological monitoring for drug resistance. To sustain support for SMC it will be 
important to document its impact on health outcomes including incidence of malaria, severe 
malaria, and child deaths. Financing plans for SMC should allow for M&E but additional research 
funding will be required to obtain more rigorous evaluation of the public health impact of SMC.  
 
Drug resistance 
Currently SP and AQ retain their efficacy in areas where SMC is envisaged. Deployment of SMC with 
SP+AQ may increase drug pressure on the malaria parasite and lead to increased parasite resistance 
to SP+AQ and it will, therefore, be necessary to monitor sensitivity of Plasmodium falciparum to SP 
and AQ in areas where SMC is used. Ensuring children receive SMC each month during the 
transmission period and that they complete the course of treatment each month, and using a 
different drug regimen for treatment of breakthrough malaria cases will reduce the selection 
pressure for resistance to SMC drugs. SMC will substantially reduce the need for and use of first line 
drugs, so using different drugs for prevention and treatment may reduce selection pressure on both 
drugs.   
 
Rebound effects 
Will SMC increase the incidence of malaria in older age groups? This is possible and it will be 
important to monitor such effects but this will require long term studies. Natural immunity is 
acquired gradually and SMC may slow this process, and as a result, older children who have received 
SMC may be at greater risk of malaria than children of the same age who have not received SMC. 
However, even if a modest increase in the incidence of malaria is seen in the year after treatment is 
stopped, the balance will still be strongly in favour of SMC because of the many deaths and cases of 
malaria it is likely to have prevented in the first few years of a child’s life. Young children should be 
protected against malaria because they are especially vulnerable, due to other infections and 
malnutrition which are more common in this age group.  
 
Pharmacovigilance 
Existing national systems are weak, SMC is an opportunity to strengthen these systems by providing 
guidelines on the recognition and management of adverse drug reactions, making sure forms are 
designed to capture relevant information and taking steps to ensure reporting forms are used and 
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are submitted or collected regularly, and the results collated and made available to health staff. 
Although there are now extensive data demonstrating the safety of SMC with SP+AQ, it will still be 
important to maintain adequate monitoring for adverse drug reactions in areas where SMC is used.  
 
Conclusions 
 
About 25million children under 5 years of age live in areas of highly seasonal transmission in the 
Sahel and sub-Sahel, and in many parts of this region malaria remains the leading cause of severe 
illness and death in children. SMC provides a very high degree of personal protection and, if widely 
deployed, could prevent a substantial proportion of the deaths and severe illnesses caused by 
malaria in these children. It is, therefore, vital that steps are taken to ensure SMC is introduced 
without delay in suitable areas.  
 
Key points from the meeting 
1.  In order to seek financing for SMC it needs first to be incorporated into national strategic plans 
for malaria control. 
2. SMC is most appropriate where transmission is high and in these areas the burden will be mainly 
in young children. Some countries have considered extending the age range. Whether this is done s 
should be based on the age pattern of confirmed cases in the areas targeted for SMC and not from 
aggregated national data. 
3. Febrile illnesses in children who have received SMC are much less likely to be malaria than in 
children who have not received SMC and it is, therefore, highly desirable to ensure RDTs are used to 
confirm malaria before treatment is given in areas where SMC is deployed. 
4. In countries with both seasonal and year-round transmission, introduction of IPTi may be 
considered for areas with high year round transmission where SMC is not appropriate. Where 
transmission is very low, other strategies may be required. 
5. Collation of data on seasonality of confirmed malaria, and the age distribution of inpatient cases, 
in the Sahel subregion should be organised in order to map in more detail areas where SMC may be 
useful. 
6. Monitoring and evaluation should be included in plans for financing SMC. Rigorous evaluation of 
the public health impact of SMCwill require input from researchers and additional resources.  
7. Pharmacovigilance  systems need strengthening. 
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Table 1: Questions that NMCP representatives were asked in relation to plans for SMC delivery 
Current policies and capacity: 
Which drugs are used for first line treatment for uncomplicated malaria? 
What is the policy with regard to parasitological diagnosis of malaria?  
- Are RDTs used at community level?  
- What % of malaria treatments are based on parasitological confirmation? 
What existing CHW/ASC schemes are in place, how widespread are these?  
- Are there malaria community case management schemes?  
- How widespread?  
- Do these use RDTs? 
Is there a national pharmacovigilance system in place for antimalarials; does it need strengthening? 
SMC implementation: 
What are the plans to include SMC in malaria control?  
- Where will SMC be implemented?  
- When (which months of the year will it be given)?  
- What is the age range of children to be included? 
What is the approximate size of the population of children to be covered? 
Will SMC be introduced in a phased manner or in all regions at once? 
What is the planned delivery approach:  
- through mass campaigns,  
- through Community Case Management schemes for malaria?  
- a mixture of both strategies? 
Drug supply chain: 
- will SMC drugs be supplied through existing channel for antimalarials? 
- will special arrangements be required? 
Policy process – has the process started and if so what stage have you reached? 
- NMCP policy document drafted?  
- Local implementation guide prepared?  
- National consensus meetings held?  
- When is validation of the policy by the Ministry of Health anticipated? 
Have any pilot studies of SMC implementation been done? 
Is there information about resistance to SP and AQ that could serve as a baseline for monitoring? 
Are there any plans for IPTi implementation in areas not suited to SMC?  
What are the plans for monitoring and evaluation of SMC? 
 
 
  
9 
 
Table 2: Country profiles – malaria treatment policy, CCM schemes, and pharmacovigilance systems  
 
Country 
First line 
Treatment   
Patients of all ages 
should receive 
diagnostic test (date 
policy adopted) 
RDTs used at 
community 
level (policy 
date) 
% malaria 
treatments 
based on 
parasitological 
confirmation 
(*by policy) 
Existing CHW/ASC 
schemes  
National PV system 
1 – A strong national 
system exists;  
2 – A national system 
exists, but needs 
strengthening;  
3 - No national 
system exists. 
Burkina 
Faso 
ASAQ 
AL Yes (2009)  20% 
National PECADOM 
scheme 2 
Chad ASAQ Yes Yes 20%  3 
Gambia AL Yes No 100%* Existing CCM scheme in most villages 2 
Ghana 
ASAQ 
AL 
DHA-PQ 
Yes (2008) Yes (2009) 100%* 
CHPS and HBC 
CCM in most districts, 
will be expanded with 
SMC 
2 
Guinea ASAQ Yes (2009) No 0% Low coverage of CHWs 2 
Guinea 
Bissau AL Yes (2008)  62% Trained ASC 2 
Mali AL Yes (2008) Yes (2005) 32% Network of relais communautaire exists 2 
Niger 
 
 
ASAQ 
AL 
DHA-PQ 
No Yes (2006) 20%  2 
Nigeria ASAQ AL Yes (2006) No 100%* CCM in all states 1 
Senegal AL Yes (2007) Yes (2008) 100%* 
PECADOM in 
communities >5 km from 
a health facility 
2 
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Table 3: Plans for implementation 
 
 
Areas 
Age range for 
SMC 
Estimated 
population 
eligible for 
SMC in the 
targetted area 
No of 
months 
SMC Jun Jul Aug Sep Oct Nov 
Burkina 
Faso 6/13 regions 3-59mths 1050805 4 
  
X X X X 
Chad 
19/22 regions 3-59mths 2301431 4 
 
X X X X 
 Gambia CRD,URD 3-59mths 52643 4 
  
X X X X 
Ghana 3 Northern Regions 3-59mths 548338 4 X X X X  
 
Guinea Siguiri, Dinguiraye, Mali Koundara  3mths to 10 yrs 169459 4 X X X X 
  
Guinea 
Bissau 
Bafata, Bissau, Biombo, 
Gabu 3-59mths 160989 4 
 
X X X X 
 
      
X X X X 
Mali 
9 régions (?) 3-59mths 3228430 4  X X X X  
      
X X X X 
Niger 7/8 regions 3-59mths 3383774 4 
  
X X X X 
Nigeria 11 Northern States 3-59mths 11208504 4 
  
X X X X 
Senegal 
Tambacounda, 
Kedougou, Kolda,  3mths to 10 yrs 535329 4 
 
X X X X 
 
      
X X X X 
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Table 4: SMC policy and implementation plans: 
 
 
 
 
 
 
 
 
 
 
 
 
 
Country Delivery Policy Plan Supply chain 
Burkina Faso Campaign 
Stratégie déjà adoptée dans 
la politique  
Stepped 6 districts in 2013, 
20 districts in 2014, all 29 
districts in 2015 
Non. L'approvisionnement des 
médicaments sera fait en 
collaboration avec la DGPML/DAF 
Chad Campaign 
Process ongoing, expect to 
adopt early 2013 Stepped 2013-2015 
au travers de l'approvisionnement 
de routine 
Gambia 
CCM 
(VHWs) 
Policy process  and 
adoption during  2013 
Stepped over 3 years  2013- 
2015  
Through existing  supply 
management system. 
Ghana 
Community 
volunteers Not started Yet to be developed 
Central and Regional Medical 
Stores,  to districts 
Guinea 
CCM and 
Campaign Expect to adopt 2012 
Stepped, 2 districts in 2013 
and 4 in 2014 Chaine nationale PCG 
Guinea Bissau 
CCM and 
Campaign Expect to adopt 2012 
Stepped 2 regions in 2013 
and 4 in 2014 
Chaine nationale 
d'approvisionnement 
Mali Campaign 
 
Steped 1 district in 2012, 5 
districts in 2013 SDADME 
Niger 
CCM and 
Campaign 
Process ongoing, expect to 
adopt end 2012 Stepped 2013-2015 
au travers de l'approvisionnement 
de routine 
Nigeria 
Village 
Health 
Volunteers Not started Yet to be developed 
Through primary health care 
facilities 
Senegal 
CCM+ 
campaign 
Process ongoing, expect to 
adopt end 2012 
Stepped over 2 years 2012 in 
1 district (Saraya) & from 
2013 in all 4 regions 
Through existing district supply 
from regional pharmacy, 
distributed to villages via health 
postes/huts 
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Table 5: Plans for M&E and plans for IPTi in areas not suited for SMC:  
Country Plans for M&E 
Baseline resistance 
data for SP+AQ 
SMC pilot 
experience 
Plan for IPTi in 
areas of year-
round 
transmission 
Burkina Faso Monitorage journalier durant la campagne; utilisation du SNIS Yes No 
Planned but 
not yet 
implemented 
Chad Surveillance de routine, enquêtes de couverture, études d'efficacité par les instituts de recherches Yes in 1 district Yes Not applicable 
Mali SLIS, SE specifique SMC Yes Yes Not applicable 
Gambia 
Baseline survey 2013 using routine HMIS tool.  
Routine HMIS data process. 
Incorporate in MIS  
Health facility survey 
Yes No Not applicable 
Ghana Outcome and impact sureveys Some data available No No plans 
Guinea 
Monitorage de routine du processus et impacts dans les 
Services de Santé; Enquêtes de couverture et 
d'efficacité Résistances aux médicaments. 
No No Planned 
Guinea Bissau 
Surveillance dans les services de Santé ; Enauëtes 
communautaire de couverture, suivi de la mortalité 
dans la HDSS, Suivi de résistance aux médicaments et 
recherche opérationnelle 
No No No plans 
Niger Surveillance de routine, enquêtes de couverture, études d'efficacité  par les instituts de recherches Yes in 1 district No Not applicable 
Nigeria Routine IDSR, M&E 
National DTET every 2 
years for treatment 
drugs 
No No plans 
Senegal 
Routine monitoring of process and outcome; coverage 
surveys (annual DHS from now on); surveillance data in 
health facilties 
Yes in 1 of the 3 
regions Yes Not applicable 
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Fig 1. The incidence of malaria in children under 5 years, and in children over 5 years and adults, in 
Senegal, by health district. Districts are ordered by the incidence among children under 5 years. 
(Data courtesy of the PNLP, Dakar, Senegal).   
 
 
Fig 2. Map showing areas where SMC implementation is planned. 
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Fig 3: Estimated number of children <5yrs in areas targeted for SMC (<10yrs for Senegal and Guinea) 
(Total:22.6million). 
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